Form 4: Bristol-Myers Squibb Director Acquires DSUs

Bristol-Myers Squibb Director Derica W. Rice acquired 695.217 Deferred Share Units, increasing total beneficial ownership to 34,934.653 units.

Summary

• Director Derica W. Rice acquired 695.217 Deferred Share Units (DSUs) of Bristol-Myers Squibb Company.
• The transaction date for the acquisition was December 31, 2025.
• Each DSU is convertible into one share of common stock upon settlement.
• Settlement occurs when the reporting person ceases to be a director or at a future specified date.
• Following this transaction, Derica W. Rice beneficially owns a total of 34,934.653 Deferred Share Units.
• The total beneficial ownership includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.

Sentiment

Score: 6

Explanation: The acquisition of Deferred Share Units by a director, as part of a compensation plan, is a neutral to slightly positive event, indicating continued alignment of interests but not a significant market-moving transaction.

Positives

• An increase in a director's beneficial ownership, even through deferred compensation, can signal continued alignment of interests with shareholders.

Negatives

• No direct negatives identified from this routine compensation-related acquisition.

Future Outlook

The Deferred Share Units will be converted into common stock upon the reporting person ceasing to be a director or at a future date previously specified by the reporting person, indicating a future conversion event.

Industry Context

This filing represents a routine insider transaction related to director compensation within the pharmaceutical industry. Such transactions are common for non-employee directors and typically reflect standard compensation practices rather than specific market or industry trends.

Comparison to Industry Standards

• The acquisition of Deferred Share Units as part of director compensation is a standard practice across many industries, including pharmaceuticals, to align director interests with long-term shareholder value. Companies like Pfizer (PFE) and Merck (MRK) also utilize similar equity-based compensation structures for their non-employee directors.
• The specific amount of DSUs acquired (695.217) and the total beneficial ownership (34,934.653) are specific to Bristol-Myers Squibb's compensation plan and individual director's tenure, making direct numerical comparison to other companies' specific director holdings less relevant without detailed compensation plan analysis.

Related Party Transactions

• The acquisition of Deferred Share Units by a director as part of a compensation plan constitutes a related party transaction, specifically director compensation.

Stakeholder Impact

• Shareholders: The increase in director equity ownership, even through compensation, generally aligns director interests with shareholder value over the long term.
• Employees: No direct impact on employees is indicated.
• Customers/Suppliers/Creditors: No direct impact on these stakeholders is indicated.

Next Steps

• The Deferred Share Units will be converted into shares of common stock upon the reporting person ceasing to be a director or at a future date previously specified.

Key Dates

Recommendation

This Form 4 filing details a routine acquisition of Deferred Share Units by a director as part of their compensation plan. While it indicates continued alignment of interests, it is not an open market purchase and does not provide new fundamental information that would warrant a change in investment recommendation. The transaction is expected and does not suggest any significant positive or negative shifts in the company's outlook.

Keywords

Bristol-Myers Squibb, BMY, Form 4, Insider Transaction, Deferred Share Units, Director Compensation, Equity Acquisition